

IN THE CLAIMS

1-5. (Canceled)

6. (Currently Amended) Method of treatment or prevention of a neurodegenerative disease of the central nervous system wherein a therapeutically effective amount of a chemical substance selected from ~~the group consisting of~~ N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an optically active enantiomer or mixture of enantiomers thereof and a pharmaceutically acceptable salt of the ~~racemic or~~ optically active ~~compound~~ enantiomer or mixture of enantiomers thereof is administered to a patient.

7. (Original) A method as claimed in claim 6 wherein the chemical substance is (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.

8. (Original) A method as claimed in claim 7 wherein the chemical substance is a salt of (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride.

9. (Original) A method as claimed in claim 8, wherein the chemical substance is (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate.

10. (Currently Amended) A method as claimed in any of claims 6 to 9 wherein the neurodegenerative disease is amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, and central nervous system neuropathies.

11. (New) A method as claimed in claim 10, wherein the neurodegenerative disease is amyotrophic lateral sclerosis.